

Microba Appoints Senior US Sales Lead

- **Appointment of Vice President Sales - North America, Mr Patrick Moelk**
- **Mr Moelk brings over 15 years' experience in diagnostics and medical sales, including specialist sales roles with genetic testing leaders Natera, Inc and Myriad Genetics, Inc in New York, United States.**
- **Mr Moelk will lead sales activities to expand distribution of Microba's testing solutions in North America**

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce the appointment of Vice President Sales - North America for Microba's Personal Testing business, Mr Patrick Moelk.

Mr Moelk commences his employment with Microba today, Monday, 9 May, and will be leading US sales activities to drive further distribution growth for the Company's suite of microbiome testing solutions.

Mr Moelk has over 15 years of demonstrated experience within the diagnostics and medical sales industry in the US, including market-leading, genetic testing companies Natera, Inc. and Myriad Genetics, Inc.

Commenting on the appointment, Senior Vice President, Platform Solutions Bernie Woodcroft said, "Consumers and practitioners are becoming increasingly aware of the effectiveness of gut microbiome testing as part of health management. With the appointment of Patrick, Microba will accelerate its rapid deployment of testing technology into new distribution partnerships throughout North America to capture this growing demand."

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.